{"id":53433,"date":"2025-09-21T23:08:35","date_gmt":"2025-09-22T03:08:35","guid":{"rendered":"https:\/\/stockmarketwatch.com\/stock-market-news\/gmo-forecasts-negative-real-returns-for-u-s-large-cap-stocks-through-2032\/53433\/"},"modified":"2025-09-21T23:08:35","modified_gmt":"2025-09-22T03:08:35","slug":"gmo-forecasts-negative-real-returns-for-u-s-large-cap-stocks-through-2032","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/gmo-forecasts-negative-real-returns-for-u-s-large-cap-stocks-through-2032\/53433\/","title":{"rendered":"GMO Forecasts Negative Real Returns for U.S. Large-Cap Stocks Through 2032"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>GMO projects U.S. large-cap stocks to deliver real returns between -2.7% and -5.7% annually through 2032<\/strong>, reflecting a continued bearish outlook on overvalued domestic equities.<\/li>\n<li>The investment firm&#39;s latest forecasts, including a <strong>-5.4% real return for U.S. Large Caps as of June 30, 2025<\/strong>, signal a challenging environment for traditional U.S. equity allocations.<\/li>\n<li><strong>GMO recommends diversifying into undervalued international and deep value segments<\/strong>, with Japan Small Value and International Deep Value offering the highest anticipated real returns.<\/li>\n<li>This outlook reinforces GMO&#39;s long-standing caution regarding <strong>extended U.S. valuations<\/strong>, advocating for a shift towards more fundamentally attractive global markets.<\/li>\n<\/ul>\n<p>Leading investment management firm GMO (<a href=\"\/stock\/GMO\">GMO<\/a>) anticipates a period of negative real returns for U.S. large-cap stocks, projecting an annualized decline of <strong>-2.7% to -5.7%<\/strong> through 2032. This forecast underscores the firm&#39;s persistent bearish stance on the valuation of major U.S. equities, suggesting that investors should temper expectations for domestic market performance over the next seven years.<\/p>\n<p>The updated outlook aligns with GMO&#39;s recent 7-Year Asset Class Forecasts. As of June 30, 2025 (Q2 2025), the firm specifically projected U.S. Large Caps to deliver a <strong>-5.4%<\/strong> real return annually. This follows a Q1 2025 forecast (as of March 31, 2025) that estimated a <strong>-4.6%<\/strong> annualized real return for the same asset class. These figures highlight GMO&#39;s consistent view that U.S. equities remain significantly overvalued.<\/p>\n<h2>Overvaluation Driving Negative Projections<\/h2>\n<p>GMO&#39;s analysis attributes the bleak forecast for U.S. large-cap stocks primarily to their <em>extended valuations<\/em>. The firm, co-founded by renowned market strategist Jeremy Grantham, has historically warned against periods of market exuberance and overvaluation. This current projection continues that theme, suggesting that current prices do not reflect sustainable future earnings or growth.<\/p>\n<p>The investment firm&#39;s model, which emphasizes historical mean reversion and valuation, indicates that U.S. equities are among the most overvalued assets globally. This contrasts sharply with other market segments that GMO identifies as offering more compelling investment opportunities.<\/p>\n<h2>Opportunities in Undervalued Global Markets<\/h2>\n<p>In light of the challenging outlook for U.S. large-cap stocks, GMO advocates for strategic diversification into <em>undervalued international markets and specific equity segments<\/em>. The firm&#39;s Q2 2025 forecast identifies Japan Small Value as topping the return expectations with a <strong>7.7%<\/strong> annualized real return. International Deep Value and Emerging Value also present strong prospects, with projected real returns of <strong>7.2%<\/strong> and <strong>6.3%<\/strong>, respectively.<\/p>\n<p>Even within the U.S. market, GMO sees pockets of opportunity. U.S. Deep Value stocks are expected to outperform significantly, with a forecast of <strong>5.6%<\/strong> real returns. This suggests that while broad U.S. large-cap exposure may face headwinds, selective investment in fundamentally sound, undervalued domestic companies could still yield positive results.<\/p>\n<h2>A Call for Contrarian Investment<\/h2>\n<p>GMO&#39;s long-term forecasts often take a contrarian view, urging investors to look beyond popular, highly valued assets. The current outlook for 2032 reinforces this philosophy, advising a shift away from overextended U.S. large-cap positions towards areas with more attractive fundamentals and lower valuations. This strategy aims to capitalize on the historical tendency for asset classes to revert to their mean valuations over time.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways GMO projects U.S. large-cap stocks to deliver real returns between -2.7% and -5.7% annually through 2032, reflecting a [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[11252,2280,4386,5201,11246,11247,11248,11249,11250,11251],"class_list":["post-53433","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-small-cap-equities","tag-gmo","tag-investment-strategy","tag-emerging-markets","tag-u-s-large-cap-stocks","tag-market-forecast","tag-asset-allocation","tag-jeremy-grantham","tag-negative-returns","tag-value-investing"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/53433","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=53433"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/53433\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=53433"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=53433"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=53433"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}